*The primary endpoints were percentage change in 28-day focal seizure frequency from baseline analysed in the modified intention-to-treat population, and responder rates (≥50% reduction) analysed in the maintenance phase population.1 Seizure freedom was a secondary endpoint of the pivotal phase II trial C017; the primary endpoint was seizure reduction.1 This webpage is intended for United Kingdom and Ireland healthcare professionals.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Adverse events and product complaint should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard for the UK or www.hpra.ie for Ireland. Adverse events and product complaint should also be reported to Angelini Pharma on (UK) +44 2034889643, (IRE) +353 1 584 4671 or UKIReporting@angelinipharma.com
Reference: 1. Krauss GL, et al. Lancet Neurol. 2020;19(1):38-48.
MAT-UKI-0062-P | November 2024
HarmoniaMentis